In this episode of Pharma Sessions, host Jonathan Kaskey interviews Dr. Huma Qamar, Head of Clinical Development and Medical Affairs at Ocugen, Inc. With her extensive background in clinical research and medicine, Dr. Qamar has been a pioneer in merging these two fields. Throughout this episode, she shares her invaluable insights on gene therapy, specifically focusing on inherited retinal diseases. Here are the top five things you'll learn: 1. The importance of patient-centered outcomes re... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00One patient changed.
SPEAKER_01This is a test to see how everything will sound.
SPEAKER_00And that patient research, and the patient was a young child, and the patient said that I want to live, I want to see the birds. And I think for me it is emotional. For me, I want to address the patient unmet medical needs. And I feel like my staff, when they look at me, they see that she's very committed. There is no day, night. There is something that I want to do for them.
SPEAKER_01Hello, hello, and welcome to Pharma Sessions, where medical affairs professionals can come to learn from each other. This is the first episode after a summer break, and there's a ton of good ones to follow, but today we dive deep into the world of gene therapy's medafairs with our special guest, Dr. Huma Kumar. Dr. Kumar is a highly regarded expert in med affairs, bringing extensive experience and insights to the table. She's had quite a journey from Pakistan to Yale, Harvard, Dana Farber, and many other prestigious institutions before joining Pharma.
SPEAKER_01We talk about challenges and opportunities of developing gene therapies for rare diseases, the importance of understanding patient-centered outcomes, the significance of clinical trial protocols, and the essential role of key opinion leaders, clinicians, and experts in designing effective protocols for success. One of the key takeaways from this conversation is the evolving landscape of gene therapy. Dr. Kamara predicts that gene therapy will play a significant role in healthcare within the next decade, revolutionizing the treatment of inherited diseases and improving quality of life.
SPEAKER_01Furthermore, Dr. Kamara emphasizes the crucial role of medical affairs as the glue that holds different pieces together in the pharmaceutical industry. Acting as a liaison between research and development teams and the clinic, Metafair serves as the foundation that ensures the successful approval and implementation of innovative therapies. I hope you feel as inspired by Dr. Kumar's passion as I do. So let's dive right in.
SPEAKER_00I am Huma Kumar. I'm the head of clinical development and medical affairs at Occugen. We are a patient-centric biotechnology mid-size pharma, and what we are focusing on is our primary uh products are in gene therapy slash ocular program, and we are also overseeing vaccine and cell therapy programs. What my role is here, I'm seeing in the entire clinical department, clinical development and medical affairs in all of the above therapeutic areas.
SPEAKER_00I have started my journey in clinical research slash medicine and surgery almost 18 years back. I graduated as a journal physician in Pakistan somewhat in late 2010. And what got me to the clinical research medicine slash surgery world was my scholarship from Yale, and that changed my life altogether. The life-changing moment happened when at Yale University School of Medicine, I gave it a little bit more thought that it's just not only the data collection that we do, and from there looking at patient-centered outcomes research, looking at the therapeutic indication, and looking at the clinical trials as a whole from phase one to four put me on the track where I felt like thinking outside the box.
SPEAKER_00Or in fact, for me, there is no box to start with. Let's take your career to the next level. After that, there was no turning back. I've worked at various academic institutions and I've served in various leadership roles. I have been in the medical science liaison positions and the national training liaison roles that I've held. And last but not the least, a couple of years ago, my focus uh was more on the medical affairs and the clinical development. And I became the head of vaccines at the Archujan. And from there I took a very different, I would say, almost 260-degree turn, and I became the head of a gene therapy program at the clinical development and started overseeing MedAffairs.
SPEAKER_01Um, what after all, that was that's an amazing background, right? So I heard general practitioner, right? Then academic, researcher, administrator, clinic starting in the vaccines and now into gene therapies. What attracted you to gene therapies with all these potential paths to choose from?
SPEAKER_00That's a great question. I as I said that I do not think outside the box. In fact, there's no box to start with. So what actually intrigued me about my current role was that every time that I've been into a position, it has to give me some challenge, it has to address patient unmet medical needs. And it has to be that rare where I am creating a difference or I'm working on some novel platforms that are going to change the lives of patients. And that was one such opportunity that I got here and I was promoted to oversee this program.
SPEAKER_00And that the reason being was that there was no as-such cure for certain mutations or it what inherited retinal diseases is posing the risk to the quality of life of these patients throughout the globe. And what in excited me was their modifier, novel modifier gene agnostic platform, where we are not looking at just the gene editing or gene replacement. We are actually looking at a very holistic approach where we are resetting the homeostasis and we are improving the quality of life.
SPEAKER_00So as our inventor of the program, uh Dr. Nina Hadder from Harvard created this uh wonderful technology. And as she says, and I would like to quote as well, is that one bad apple spoils the bunch, right? So here, if you look at the gene de facto, the gene mutation, there is what this particular technology does is that it fixes the entire problem rather than just going gene by gene or mutation by mutation. So it's an agnostic approach, and that was something that I was very keen about, and I wanted to really address the patient unmet medical needs and improving their quality of life, and of course, potentially or therapeutically long-term cured blindness.
SPEAKER_01Wow, that's amazing. And it's so what you're describing is so cutting-edge because it sounds like again, I'm a much I'm a lay person essentially, right? But this is not just even not just your standard gene therapies, right? This is an advanced set of gene therapies. So that brings me to the medical affairs question, where so much of medical affairs is taking data or taking this information and communicating it to various audiences, whether they're the providers, the researchers, the patients, the payers, or H E O R government agencies, you name it.
SPEAKER_01So, how have you found that kind of that level of complexity? How do you address that as you're trying to create Medcom strategy and the like for all these different groups?
SPEAKER_00This is a great question, and I wish there was a specific answer to that. But yes, I have found uh a way to figure out, first of all, what the issue is, and as you know, that there is always tip of the iceberg and Titanic sink tank because of uh there was like as the glacier was just the tip was there, and we couldn't appreciate all the other factors that go besides that. So, in terms of this one, in terms of gene therapy, what I have when I started, I literally had to uh think through it what the scope or the magnitude of the problem is.
SPEAKER_00And I had to see from patients' perspective first, because see, I come from that training, but also from when you are sitting at the pharma and in the small biotech company, it's very difficult that you are coming up with something very unusual. And how are you going to address it? You have not done this before. Are there any guidelines? Because there are not many FDA guidelines out there, is only one approved product, as you all know, in 2018 was Lexterna. And the only thing that there was, and it's also addressing uh a handful of mutations, although it's a great framework for us that we want to proceed with that, but um it was largely due to better clinical and uh scientific understanding of the safety profiles, and uh not only that, it was patient-reported outcomes that they were looking into it.
SPEAKER_00But the major question that I had in my mind was that how it's going to work out, even from clinical development or medical affairs perspective, how we are going to roll this out, even from the study design, like what kind of study design we could have, although it is safety, but we also want to look at it from an efficacy perspective because these patients are coming to us with hope. I'll tell you that I get a lot of emails from like all across the world, hundreds of emails, and there is something for our mutation. Are you doing something?
SPEAKER_00So I think the standards required in terms of regulatory were not one-stop shop. And there is no right or wrong answer. Because if you look at it, the rare diseases tend to have clear genomic targets, but still there is unmet medical need because there is a small population, it's undersolved. But I think for me, the most important thing that was in this was innovation. And I believe in the theory of division of innovation. So I can talk more about it if you will.
SPEAKER_01I have a question on something you said actually. I feel like the Titanic metaphor is a really good one, right? Because it gets the idea of there's what and then there's what you don't see, and what you don't see, or like in this case, maybe what doctors don't know they should be concerned about, can be really important, but yet you're dealing with this in a rare disease space. So I'm curious, like the nuts and bolts of it, were you using standard insight gathering methods of ad boards and the like, or are there different approaches you have to take to being in rare disease to understand what do they know, what do they not know, and then even when you're talking about clinical trial design, what are the endpoints that we're shooting for?
SPEAKER_01And are those gonna address the concerns that they have or that they should have?
SPEAKER_00Yes, and I think the answer to this is twofold. First of all, you should know what your population is, where the population is, and what is the magnitude of the disease in terms of from cost perspective and also clinically, and pathophysiology is important. Also, what do you want to achieve? And when do you want to achieve? And whatever is Bakstana did a great job for us actually. They they put us in a path where we saw that okay, there is hope for these uh patients. However, one thing I would like to mention here is that, and I'm not making it a tall claim on that, is that the smaller biotech companies have made substantially a lot more progress in terms of taking these challenges where there is unmet medical need, particularly in gene therapies, as compared to the bigger ones, because the amount of work that it takes to make these platforms or from manufacturing perspective or from the pre-clinical side to get to the clinical one is is substantial.
SPEAKER_00Some companies have spent decades, and uh, when they go to the clinical uh part that the science scientific question becomes too old or their product is not able to address that. So these are the challenges that we are looking into. So, in terms of clinical, I'll tell you that innovative clinical trial designs are important because the patient population is small. Yeah, sometimes when you're trying to make these designs, I will tell you that's not statistically significant. It's not a vaccine trial, it's easier to have 200, 400, get the vaccine shot on COVID or something.
SPEAKER_00I've done that trial, it's great. But in order for us to address the unmet medical needs and allow these therapies to go to the market faster, there are clinical questions that require accelerated pathways, and that becomes a regulatory challenge. What is the do and don'ts in terms of getting to the agency? For example, this particular products that we deal with are AEV-based therapies, and they are very sensitive to what is the durability of response. If there are any antibodies against AAV, I'm just being very specific here, is that can prevent additional dosing and maybe may lead to warning the response.
SPEAKER_01Right.
SPEAKER_00And also pre-existing immune reactions and what has been done in the field. But for us, when we were doing this modifier gene therapy platform, there was no as such comparable technology because it's novel in the world that we are talking about.
SPEAKER_01So you it's amazing, right? Because it's not only do you need to understand this incredibly complex science and map out clinical, but you also need to understand the regulatory concerns of payers that are government organizations, and they're all different, right? So, how do you, as a relatively smaller company compared to some of the massive ones out there, how do you manage that? This episode is sponsored by Structured Meetings.
SPEAKER_01It's a Teams app that turns your own Teams incidents into the perfect advisory board platform to save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com.
SPEAKER_00Yeah, so when we talk about the pairs, I'll tell you a little bit about that. Most of the patients, first of all, they don't know that there are clinical trials happening. I'll talk about a simple gene mutation which is CEP290, which is lever congenital emerosis. And technically, some of the patients are labeled as legally blind. Now, this is a very specific population, there are different mutations, LCA 1 to 13. So LCA 10 is the most common. I'm talking about the most common type. And it is much difficult to even reach out to them and tell them that okay, there is a product.
SPEAKER_00They have tried everything. Maybe there was an intravitral approach, there was some other gene therapy that they have done. So from the patient perspective, when they go to these new trials, there is an inclusion exclusion criteria that tells them that you should be the first one to be enrolled in our trial. And that becomes really difficult for them because that trial either has failed or has not, or it was maybe two five years, four years, or two years back, but they have no choice because they are not meeting the inclusion exclusion criteria where they have the last hope right now. And we are not claiming that that's gonna be giving the signal right away, but of course the efficacy outcomes are important.
SPEAKER_00So when we look at the payers' perspective, the clinical trial, these clinical trials are very expensive. For example, for these kind of trials, and you look at gene therapy, most of them are now going subretinal. And subretinal injections are really expensive, they are from take a lot of time and toll on uh the clinical sites to develop their entire infrastructure, and there are a handful of surgeons, vitoretinal surgeons in the United States that do that. And for me to develop that kind of strategy with them and to which uh technique they have to use, I have to come up with certain clinical trial design and the payer perspective that how is it gonna work out for them?
SPEAKER_00Not only that, keep in mind these patients are not the patients that are just gonna come and we are gonna compensate for the travel lodging and facility and all of those kinds of things. They have caregivers, they have other needs. This, these tests that we do requires a lot of genetic testing. Some of them have gone and got their genetic testing maybe years, 20 years ago. So they don't even know what their pathogenic variants are. And that's where I think might be your next question to me that where is the gap? And the gap is where the clinical diagnosis from where it started 15, 20 years ago versus what it is right now.
SPEAKER_00And having that in mind, having the clear picture, it's very difficult when a panel of people are sitting and it's so complex to even read that report and to tell them that okay, you are not gonna be part of our trial, but what does it take to be part of our trial? Because I'll tell you, in terms of payments, providers and hospitals, the CMS new guidelines are probably hopefully gonna address that, but there are no guidelines as such where they are have made substantially any rules or regulations for the gene therapy, particularly in the ocular space.
SPEAKER_00Let alone I'll tell you the CTCA criteria, which is the common terminology criteria for adverse events when we look into it, is more for the oncology. There is a standard format that they have. Now, with me, if I have to grade them and look at them, that is also different. That is not even there. So we are dealing with multiple challenges, and when we don't have those classifications, we cannot go to the insurance and work with their insurance. So the small biotech companies have to actually assume all the trial-related costs, which takes a lot of burden.
SPEAKER_00For example, in hemophilia, you know that the blood transmissions for hemophilia are there, but not only that, there is a single high-price dose that there is, and it potentially has a lot of risk, and in terms of monetary risk to the hospital and distribution systems. So, not only that, for the curative therapies that we're talking about, this particular ocular gene therapy, it's way more complex than that. How are you going to manage the complications? And the first therapy you are giving as an indication has how that's gonna pan out. There is no right or wrong answer, but there is a right answer to me, at least what I have I feel that there is a gap, is that there is no as such CMS guidelines to the to to that could guide us.
SPEAKER_00For example, incology, we can take here and there, right? We have very good guidelines. But in terms of gene therapy in the ocular space for IRDs for inherited retinal diseases, I think it's difficult. Most of the patients, the first time they reach out to me, is that how am I gonna get paid? What if I ad I get an adverse event? Some of them actually are coming outside from the US, and they're coming from Belgium, they're coming from Sweden, they're coming from London. That's a lot of money.
SPEAKER_01Oh, yeah. Oh, yeah. So this trial is happening solely in the US, and you're flying a bro, a small patient population is being flown internationally going through major specialized surgery, essentially, and it's being you're it's being done without guidelines, not without guidelines, you're creating the guidelines. You're responsible for creating the guidelines. Am I getting this? Am I getting this right or am I missing something?
SPEAKER_00You're absolutely getting it right, because you know what? Our long-term goal is to unlock the market access for gene therapies in the United States and to make sure that they're available for all over the people, all over the globe.
SPEAKER_01Right.
SPEAKER_00And the problem is this that if you look into it, there is much more to that.
SPEAKER_01Yeah.
SPEAKER_00Now with the AI and with the clinical development, new technologies and everything, and the patient registries, if you're looking into the confirmatory trials and innovative use of real-world data, it becomes difficult. And this is where the safety and efficacy over extended periods of time are required, which means I'll give you a simple example. Anything that you do with gene therapy, you have to follow up the patients for one year minimum. Also, there is, if you want to look at the signal or anything, it takes a couple of years and up to five years. It takes a lot of toll on the companies to have those mechanisms in place, not only on the companies, but also on the patients and families and the hospitals.
SPEAKER_00So I think it's it's it's a very tedious, yeah, yet some with some hope and passion that there is going to be some light at the end of the tunnel.
SPEAKER_01What about adherence to a clinical trial of that complexity and and duration? Do you find that patients drop out? And and how do you how do you manage that?
SPEAKER_00So I'll tell you, uh, that's a great question, actually. Uh, if it is a vaccine or any cell therapy trial, I think the dropouts can happen. But uh, luckily, on this one, at least for I can speak on the rare disease, they have no other therapies, life-changing therapies, or the company is developing life-changing therapies for them, or curing blindness are out there. So, what they do is that yes, we have not reached to that stage. Yes, there can be potential dropouts, but because of their safety and efficacy, that they're so committed. I think more than us, the patients are so committed, and you can see it, you can hear it in my voice, see it on my face, that I am so committed to that that it's the energy and the passion that comes from the patients.
SPEAKER_00That if I get something from this is my only child, right? My child has septo 90, but my child has been diagnosed that they will be going blind in a few years. How does that feel?
SPEAKER_01Oh, I can't imagine.
SPEAKER_00Exactly. Yes. So for us, we have not seen that yet. Yes, it can be an issue for the people who are maybe in the 60s or 70s, but I think for the younger individuals, the dropouts rate are not gonna be that much. But I think the issue that's becoming right now is that what I envision this gene therapy moving forward is having an integrated, like in a clinical and commercial models. I hope that's gonna be something that you know all the stakeholders, all the champions in the field should look into it.
SPEAKER_00That what's the curative nature of this and you know how the hospital economics are gonna work? How limited, what does limited patient population mean? Of course, there are handful of surgeons, winter retinal surgeons, and also there are declining number of eligible patients. Also, if they do not get the support from the pharma companies or from the hospitals, or if it's too much of a burden to do even the screening tests, I'll tell you it takes three to five days to do multiple tests, whether it's FSD, ERG, FAF, anything, that takes a lot of toll on the patient.
SPEAKER_00And also high risk price, which is associated with it. And if there are not all the things covered in one way or the other, and if they don't have insurance or if there is anything else, then that creates risk for. For for us as well. Yeah. In terms of having access to this.
SPEAKER_01Can I bring it back to the med affairs part of this, like away from the clinical? But with all those risk factors, if I'm if I am a doctor, I feel like all that kind of factors into your decision on telling people you can pursue this or you can't, and accessibility is part of it. There's a lot there, but at the same time, if this is the hope and there's no other hope, then you sometimes patients find a way. So I guess it brings back to the original question. How do you take such a complicated story and is the plan to fit it into the amount of time that an MSL gets with their doctor, which is not a lot of time, or are there other ways that you're trying to educate the doctors on this, given that it might just be too much for an MSL to have in a live conversation or reliably have in a live conversation?
SPEAKER_00Yeah, so that's that's great that you ask. I think let's start from the beginning. Okay, what is required actually in this kind of rare disease gene therapy metaphairs approach? As I said, we all know that Luxtrona was approved in 2018. If you look at the first set of promising gene therapies that were actually stopped, classic, which was in 1999, where we had the death of one of the Jesse Gelsinger from an immune reaction to the bacteria transporting, there was a metabolic disorder, and the development of leukemia by multiple patients, and safety was an issue, and these were the trials that ran between 1999 and 2002 with an X-linked deficiency.
SPEAKER_00What it is that there are two patterns, first of all, to understand overall the market. That's one thing that you know from a commercial perspective. There are three pillars, right? I always talk about it's RD, medical affairs, and commercial. Initially, it's RD, and sometimes medical affairs is embedded in RD, which is actually my current role right now that I am part of both. Okay. So clinical development and medical affairs, it goes in parallel. How this we can take it to the next level, or how do I inform the key opinion leaders is not one step, or I would say is not the classic way that you would do it with the other indications.
SPEAKER_00So what I've taken the approach, I'll tell you that, which has worked for me, is that basically the basic principles are the same. You there are, as I said, handful of surgeons, veterinal surgeons, there are a handful of gene therapy experts in the country, uh, most from the scientific perspective and also from clinical. And one of the great things that I have learned through and I have embedded in my group is that I've developed some strategic relationships and some forums where I meet with them regularly, whether it's with a regulatory agency or is it whether it's at the conferences, particularly at Arbo or AO.
SPEAKER_00Those are the two platforms, if there are any retina societies that I have to, I have developed that relationship with them. Before even going to and designing the protocol and looking at it, what we are doing, it's important to get their perspective because they have been in the field and what's going to work. For example, what's going to work in the pediatric population versus what's not going to work in in the adult. So I think that is the first step in knowing at what is that we want to achieve. Because, and across different modalities and different therapeutic areas, the things are different.
SPEAKER_00But in terms of this, right now, that if we're looking at the uh gene therapy in the IRD, I'm going to move more focus on the inherited retinal diseases because that's what I've been working on. And right now we are for I'm going towards the geographic atrophy, but that's also the gene therapy we're advancing in, and the starcar disease, which is also the IRD. So I think looking at similar pathways that what people have taken in case they are approved, but also having the KOLs who have done this and partnering with them, and not it's difficult during the COVID time, it was difficult to meet with them in one-on-one, but right now, having those key experts and talking to them, particularly, I would say that even the FDA, they're open to talk to you.
SPEAKER_00If you, if this is your product, they would your pre-clinical or talk status, how does it define your clinical design? But I think for me it has been more helpful in talking to the scientific members who have been there, who have been part of the trials, who have been there for a long time, and developing something that makes sense because they have access to the patients. I might have a research question that I might be thinking right now here and might not work for the patient. So I think it's you have to know that most of the gene therapies will come to the market under the accelerated regulatory pathway.
SPEAKER_00Or it has to be due to the regenerative medicine advanced therapy or breakthrough designation by the FDA or orphan drug designation, which expedites the approval process. So I think these are the things that go hand in hand with the key experts and also with the FDA regulatory agency that would tell you that okay, what is required and what will work and what would not work. For example, a simple thing in medical affairs that I'm giving, and I think if uh any of the clinicians are uh listening to this, they can attest to that. Best corrected visual equity is one of the uh parameters or the variables we do see in terms of vision, okay.
SPEAKER_00And what it is that what is the best vision you can achieve with your classes when you go to your optometrist or ophthalmologist to do a test. That has a certain guideline from FDA which states that we look at five letters, and if there is five letters of improvement, then it means one line. So things are changing. We need to know those nitty-gritty of things by only working with these key opinion leaders, these experts who have been on the block for years, who have worked through something which is has worked for them or has not worked for them.
SPEAKER_00But also with gene therapy, there is no right or wrong answer. You have to defend your data and you have to come up with innovation.
SPEAKER_01Yeah. One of the things I like about this approach is that you're reviewing, you're building these relationships, right? Which is important with a set of KOLs, the set of experts, and you're reviewing the protocols with them, not just understand scientifically, is this going to show proper safety or efficacy or whatever the case may be, but also is this going to fit along with the patient lives, right? Is this part, are patients going to be able to do this? And I think that's such an important part of it, the patient journey part, particularly for rare disease, because I I've been a part of conversation, like rare disease advisory boards with directly with patients, and one of the things we often hear is nobody knows what I'm going through, right?
SPEAKER_01Nobody understands this because I've never met anybody else that has this or has a child that's going through this. So keeping them front of mind, and I know that the doctors do keep them front of mind because they spend so much time with each one. I think it's really interesting to get their perspective so early as you're developing and reviewing the clinical trial protocols under the disguise of accelerated breakthrough where you're setting definitions and getting their buy-in on are these definitions make sense?
SPEAKER_01Will this show you the evidence that you need to make decisions? I think it's really fascinating. So let me ask you one final question because we've very quickly filled up the time that was allotted. I can hear the excitement come through your voice whenever you're talking about gene therapy. But if you had a matchwander or a crystal ball or whatever, and you could look at and say, okay, we're five years in the future. What's changed in gene therapies and what excites you about the potential for how things might be different or better in the future with all this stuff happening with gene therapies?
SPEAKER_00Yeah, that's that's a really good question, actually. I'm glad you're asking that. So that in the past, I would say, go let's go back a decade and people were focusing on the gene editing part, gene uh replacement and one gene and focusing on just one because they were figuring it out. And I think now gene agnostic approaches are now on the horizon, and they are basically looking at solving the issue at a much bigger level and improving the quality of life. So that I think that's where the gene um therapies are taking like the next step that's and coming up with, if you look at it, there are different modalities people are using.
SPEAKER_00Initially, there were some intravitral versus subretinal. So I think if you get a subretinal injection, you are having a gene therapy. I'm just putting not all claims here, but uh the data will prove for it's a one once-in-a-lifetime. You're going to get your results probably sooner in a couple of years, and you will probably get the quality of life in terms of your BCVA or LLVA or any type any type of other quality of life, which is like National Eye Institute questionnaire that we do see. But I think what I see from the past to now is the innovation also not going by mutation, which some are doing it, but at least I can talk on behalf of what I'm seeing is that the next 10 years, gene therapy is the future.
SPEAKER_00Gene therapy might have some limitations in terms of cost, might have some limitations in terms of the clinical trials that we're having, but I think the data that is being generated and the uh AI being now the coolest thing, I think all those real-world evidence that we are looking into. Moving forward by 2030, saying that's the mark, I think we are seeing that the quality of life and gene therapy would take on a bigger role. For example, if there is wet AMD and there is dry AMD and age-related uh macular uh degeneration, there are different conditions that are causing it, but might be a product that might do for both, and might be more prevention rather than stabilization.
SPEAKER_00So here is our goal in gene therapy. Either we stabilize or we improve or we reverse. There are three aspects that I'm looking into, and I think by 2030, I think that is the world that we are looking into, and gene therapy is definitely the future. My surgery professor used to say your eyes cannot see what your mind does not know. So I think that was a radical pancreatectomy. Whipples procedure I was doing one point, and it was very difficult longest procedure that we do, but I think that stuck with me, and I think I have taken the same approach that your eyes cannot see what your mind doesn't know.
SPEAKER_00So I think gene therapy is definitely indeed the future and our potential. I think the mission and vision that I have to cure blindness.
SPEAKER_01Wonderful. All right, let's leave it there on that sentiment of hope. This episode is sponsored by structured meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and not to brag, but my clients have did more events than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise. One of the questions I used to get all the time was, can we just do this in teams? And the answer back then was not really.
SPEAKER_01Teams out of the box is clunky and not fit for purpose. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own teams incidents. It changes teams just enough to check all the boxes for what's needed for great ad boards. And also, it's super fast and it saves people a ton of money. Visit www.structured meetings.com for more info. All right, well, back to the show.
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...
In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...
Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...
What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...
What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...